Completion of delisting from ASX

RNS Number : 1804L
Litigation Capital Management Ltd
21 December 2018
 

21 December 2018

 

Litigation Capital Management Limited
("LCM" or the "Company")

 

Completion of delisting from ASX

 

Litigation Capital Management Limited (AIM:LIT), a leading international provider of litigation financing solutions, announces the delisting of its shares from the Australian Securities Exchange ("ASX") was completed with effect from market close on 21 December 2018, in Sydney, Australia.

 

There is no impact on the trading of LCM on the Alternative Investment Market ("AIM") in London and this is now the Company's sole and primary listing.

 

-ENDS-

 

CONTACTS

 

Litigation Capital Management

Patrick Moloney, Chief Executive Officer                             

Nick Rowles-Davies, Executive Director

 

Canaccord (Nomad and Broker)                                                Tel: 020 7523 8000

Sunil Duggal / Emma Gabriel / Michael Reynolds

 

Hawthorn Advisors                                                                      lcm@hawthornadvisors.com

Lorna Cobbett / Zinka MacHale                                                 Tel: 020 3745 4960

 

NOTES TO EDITORS

 

About LCM:

Litigation Capital Management ("LCM") is a leading international provider of litigation financing solutions. This includes single-case and portfolio; across class actions, commercial claims, claims arising out of insolvency and international arbitration. LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management. Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFKKDKABDDPBB
UK 100